HEMA - HemaCare Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
3.50
+0.08 (+2.34%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close3.42
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume5,754
Market Cap36.162M
Beta1.21
PE Ratio (TTM)28.69
EPS (TTM)0.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire9 days ago

    HemaCare Announces OneBlood Exercises Second Investment Tranche Option

    HemaCare Corporation , a leading provider of human-derived primary blood cells and tissues for biomedical research, has announced a second tranche investment, effective December 28, 2017, by a wholly-owned subsidiary of OneBlood, Inc., a not-for-profit blood center based in Florida.

  • HemaCare Corp.: Leads amongst peers with strong fundamentals
    Capital Cube21 days ago

    HemaCare Corp.: Leads amongst peers with strong fundamentals

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 61. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown good ... Read more (Read more...)

  • Business Wire4 months ago

    HemaCare Plays Mission Critical Role in Global Cellular Therapy Development

    For many years, HemaCare Corporation has been at the epicenter of cellular therapy, immunotherapy, and regenerative medicine research by providing researchers from biotech and pharma companies with mission critical human biological materials from reliable and recallable donors.

  • HemaCare Corp. :HEMA-US: Earnings Analysis: For the six months ended June 30, 2017 : August 23, 2017
    Capital Cube5 months ago

    HemaCare Corp. :HEMA-US: Earnings Analysis: For the six months ended June 30, 2017 : August 23, 2017

    Categories: Yahoo FinanceGet free summary analysis HemaCare Corp. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of HemaCare Corp. – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US) that have also reported ... Read more (Read more...)

  • Business Wire5 months ago

    HemaCare Will Attend Annual CAR-TCR Conference in Boston

    HemaCare Corporation , announced today that it will be attending the annual CAR-TCR conference September 5-8, 2017, in Boston, MA. The conference is focused on the development and commercialization of cell therapy that uses the immune system to fight cancer and other diseases.

  • Business Wire5 months ago

    HemaCare Reports Strong First Half 2017 Results

    HemaCare Corporation today reported financial results for the six months ended June 30, 2017, showing continued robust gains in revenue, gross profit, and net income compared to the same period of 2016.

  • HemaCare Corp.: Strong price momentum but will it sustain?
    Capital Cube5 months ago

    HemaCare Corp.: Strong price momentum but will it sustain?

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 57. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown good ... Read more (Read more...)

  • Business Wire6 months ago

    HemaCare Signs Long Term Lease for Facility Relocation and Expansion

    HemaCare Corporation , a leading provider of human blood and immune cells for all stages of cell therapy development announced today that it has signed a long term lease to relocate its operations and corporate headquarters to a larger nearby site in the San Fernando Valley .

  • Business Wire6 months ago

    HemaCare Announces Expansion of Disease State Cells for Bioresearch

    HemaCare Corporation , a leading provider of human blood and immune cells for bioresearch announced today that it has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers.

  • HemaCare Corp.: Strong price momentum but will it sustain?
    Capital Cube7 months ago

    HemaCare Corp.: Strong price momentum but will it sustain?

    Categories: Yahoo FinanceHemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 58. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HPHW-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown overwhelming ... Read more (Read more...)

  • Business Wire7 months ago

    HemaCare Will Attend the International Society of Stem Cell Research in Boston

    HemaCare Corporation , a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Stem Cell Research June 14-17 in Boston, MA.

  • HemaCare Corp. :HEMA-US: Earnings Analysis: 2016 By the Numbers : May 4, 2017
    Capital Cube8 months ago

    HemaCare Corp. :HEMA-US: Earnings Analysis: 2016 By the Numbers : May 4, 2017

    Categories: Yahoo FinanceGet free summary analysis HemaCare Corp. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of HemaCare Corp. – Tivity Health, Inc. (TVTY-US) that have also reported for this period. Highlights Gross margins widened from 45.45% to 51.35% compared to the same period last year, ... Read more (Read more...)

  • Business Wire9 months ago

    HemaCare Will Attend International Society of Cell Therapy in London

    HemaCare Corporation , a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Cell Therapy in London, UK, May 3-6, 2017.

  • Business Wire10 months ago

    HemaCare Attends the American Association of Cancer Research Annual Meeting

    HemaCare Corporation , a leader in cell and tissue collection, processing and solutions for cell therapy, will be attending the AACR annual meeting at the Walter E. Washington Convention Center in Washington, D.C.

  • HemaCare Corp.: Leads amongst peers with strong fundamentals
    Capital Cube10 months ago

    HemaCare Corp.: Leads amongst peers with strong fundamentals

    Categories: Yahoo Finance HemaCare Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 61. Our analysis is based on comparing HemaCare Corp. with the following peers – Hooper Holmes, Inc., InfuSystem Holdings, Inc., Tivity Health, Inc., Premier Inc. Class A and CorVel Corporation (HH-US, INFU-US, TVTY-US, PINC-US and CRVL-US). HemaCare Corp. has shown good ... Read more (Read more...)

  • Business Wire10 months ago

    HemaCare Reports Strong, Profitable 2016 Results

    HemaCare Corporation today reported financial results for 2016, showing robust gains in revenue, gross profit, and net income from continuing operations compared to the prior year.

  • Business Wire11 months ago

    HemaCare Signs Distribution Agreement with Israeli-Based Partner

    HemaCare Corporation , a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in Israel with Almog Diagnostic.